Blockbuster obesity drug aims to win $4bn sales for Sanofi-Aventis

French pharmaceuticals group develops treatment for condition at the top of global health agenda

The expected green light from Brussels in the next few weeks would mean that the French giant Sanofi-Aventis could begin marketing the treatment, called rimonabant but branded as Acomplia, later this summer. It is the first of a new generation of drugs set to hit the market in the next few years that could transform obesity, still a small market, into a gold mine for the pharmaceutical industry.

Pfizer, Bayer, Eli Lilly and Merck are developing treatments similar to Acomplia, though they are further behind. Sanofi plans to launch Acomplia first in the UK, Germany, Ireland and Scandinavia.

The timing is auspicious. Governments in Europe and the US have put obesity and its associated conditions, including Type 2 diabetes, at the top of their public health agendas. The Department of Health says that more than half of all British adults - 24 million people - are either overweight or obese. In America, obesity and its complications are estimated to cost the country $70bn (£37bn) annually, according to Scrip Reports.

Gbola Amusa, an analyst with research firm Sanford C Bernstein, said that Acomplia could achieve $4.1bn in annual sales by 2010, in part because it has been shown in clinical trials not only to trim fat but to increase levels of good cholesterol and control diabetes.

"In the blue sky scenario, this could become the world's best- selling drug as the indication is so broad," he said. "It has a path to revenues that we rarely ever see from a pharma product."

The treatment is the first in a new class of drugs called canna- binoid CB-1 blockers, which suppress appetite by blocking the receptor in the brain responsible for hunger pangs, which can be stimulated by marijuana.

The Committee for Medicinal Products for Human Use (CMPH), an advisory group to the European medical regulator EMEA, recommended on 28 April that Acomplia be approved for obese patients, as well as for overweight people with Type 2 diabetes or dyslipidemia, both of which are conditions that governments usually fund. The EC follows CMPH recommendations in nearly all cases.

"We are 99.9 per cent sure of approval," a Sanofi spokesman said.

Only two prescription weight-loss drugs are on the market, and neither has had much success. Abbott's Meridia is an appetite suppressant that produces an artificial sense of being sated, but it also causes hypertension. Roche's Xenical works by blocking the body's ability to absorb fat. However, any fat ingested must be passed out of the body through the bowels, which many patients find uncomfortable.

Neither can be prescribed for any indications beyond weight loss. "It's not being obese that kills you, it's the side-effects that come along with it," said Dr Julian Mercer of the Rowett Institute. "Addressing associated risk factors is a novel aspect."

Approval in America, the world's biggest drugs market, is crucial. The US industry regulator gave an "approvable letter" for Acomplia in February, asking for more time and information before it gave its final decision. Sanofi's head of research and development, Gérard Le Fur, said at the company's annual general meeting in Paris last week that he expects to get US approval by the end of the year.

The indications for which it is approved are also important. Neither Orlistat nor Meridia qualify for reimbursement with US insurers. If the label includes Type 2 diabetes and dyslipidemia, as is expected for Europe, the chances that insurers will pay for it are much greater.

PROMOTED VIDEO
News
ebookA unique anthology of reporting and analysis of a crucial period of history
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Senior Analyst - ALM Data - Banking - Halifax

£350 - £400 per day + competitive: Orgtel: Senior Analyst, ALM Data, Halifax, ...

Java developer - Banking - London - Up to £600/day

£500 - £600 per day: Orgtel: Java developer - Banking - London - Up to £600/d...

Liquidity Reporting-Basel III-LCR-Bank-£400/day

£400 per day + competitive: Orgtel: Liquidity Reporting - Basel III - LCR - Ba...

Investment Manager – Media and Entertainment

Up to £50,000 per annum + Bonus + Benefits : Sauce Recruitment: We are repre...

Day In a Page

Save the tiger: The animals bred for bones on China’s tiger farms

The animals bred for bones on China’s tiger farms

The big cats kept in captivity to perform for paying audiences and then, when dead, their bodies used to fortify wine
A former custard factory, a Midlands bog and a Leeds cemetery all included in top 50 hidden spots in the UK

A former custard factory, a Midlands bog and a Leeds cemetery

Introducing the top 50 hidden spots in Britain
Ebola epidemic: Plagued by fear

Ebola epidemic: Plagued by fear

How a disease that has claimed fewer than 2,000 victims in its history has earned a place in the darkest corner of the public's imagination
Chris Pratt: From 'Parks and Recreation' to 'Guardians of the Galaxy'

From 'Parks and Recreation' to 'Guardians of the Galaxy'

He was homeless in Hawaii when he got his big break. Now the comic actor Chris Pratt is Hollywood's new favourite action star
How live cinema screenings can boost arts audiences

How live cinema screenings can boost arts audiences

Broadcasting plays and exhibitions to cinemas is a sure-fire box office smash
Shipping container hotels: Pop-up hotels filling a niche

Pop-up hotels filling a niche

Spending the night in a shipping container doesn't sound appealing, but these mobile crash pads are popping up at the summer's biggest events
Native American headdresses are not fashion accessories

Feather dust-up

A Canadian festival has banned Native American headwear. Haven't we been here before?
Boris Johnson's war on diesel

Boris Johnson's war on diesel

11m cars here run on diesel. It's seen as a greener alternative to unleaded petrol. So why is London's mayor on a crusade against the black pump?
5 best waterproof cameras

Splash and flash: 5 best waterproof cameras

Don't let water stop you taking snaps with one of these machines that will take you from the sand to meters deep
Louis van Gaal interview: Manchester United manager discusses tactics and rebuilding after the David Moyes era

Louis van Gaal interview

Manchester United manager discusses tactics and rebuilding after the David Moyes era
Will Gore: The goodwill shown by fans towards Alastair Cook will evaporate rapidly if India win the series

Will Gore: Outside Edge

The goodwill shown by fans towards Alastair Cook will evaporate rapidly if India win the series
The children were playing in the street with toy guns. The air strikes were tragically real

The air strikes were tragically real

The children were playing in the street with toy guns
Boozy, ignorant, intolerant, but very polite – The British, as others see us

Britain as others see us

Boozy, ignorant, intolerant, but very polite
How did our legends really begin?

How did our legends really begin?

Applying the theory of evolution to the world's many mythologies
Watch out: Lambrusco is back on the menu

Lambrusco is back on the menu

Naff Seventies corner-shop staple is this year's Aperol Spritz